Krystal Biotech is performing exceptionally good at this time. It has a great odds to report excellent financial results in March. At this time, Krystal Biotech's Capital Surpluse is comparatively stable compared to the past year. Other Current Assets is likely to gain to about 13.9 M in 2025, despite the fact that Net Debt is likely to grow to (320.7 M). Key indicators impacting Krystal Biotech's financial strength include:
The financial analysis of Krystal Biotech is a critical element in measuring its lifeblood. Investors should not minimize Krystal Biotech's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Please note, the imprecision that can be found in Krystal Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Krystal Biotech. Check Krystal Biotech's Beneish M Score to see the likelihood of Krystal Biotech's management manipulating its earnings.
Krystal Biotech Stock Summary
Krystal Biotech competes with MeiraGTx Holdings, Apellis Pharmaceuticals, Regenxbio, and Rhythm Pharmaceuticals. Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. Krystal Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Krystal Biotech's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Krystal Biotech's current stock value. Our valuation model uses many indicators to compare Krystal Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Krystal Biotech competition to find correlations between indicators driving Krystal Biotech's intrinsic value. More Info.
Krystal Biotech is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.67 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Krystal Biotech is roughly 1.50 . At this time, Krystal Biotech's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Krystal Biotech by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Krystal Biotech Systematic Risk
Krystal Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Krystal Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Krystal Biotech correlated with the market. If Beta is less than 0 Krystal Biotech generally moves in the opposite direction as compared to the market. If Krystal Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Krystal Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Krystal Biotech is generally in the same direction as the market. If Beta > 1 Krystal Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Krystal Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Krystal Biotech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Krystal Biotech growth as a starting point in their analysis.
Krystal Biotech February 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Krystal Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Krystal Biotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of Krystal Biotech based on widely used predictive technical indicators. In general, we focus on analyzing Krystal Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Krystal Biotech's daily price indicators and compare them against related drivers.
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.